MS treatment gets personal: could tailored infusions be just as effective?

NCT ID NCT05296161

Ongoing Disease control Sponsor: Amsterdam UMC, location VUmc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares the standard fixed-interval dosing of ocrelizumab (every 24 weeks) with a personalized approach where infusions are given only when B cell levels rise above a certain threshold. The goal is to see if the personalized schedule is just as good at preventing relapses and new brain lesions, while potentially reducing side effects and costs. The trial involves 296 adults with relapsing-remitting MS who have already been on ocrelizumab for at least a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ocrelizumab (Ocrevus)
What this could lead to: If successful, this could lead to a more personalized, safer, and cheaper way to manage relapsing-remitting MS by tailoring infusion intervals to each patient's immune response.
What could go wrong: This is a Phase 4 trial, so the drug is already approved. The main question is whether personalized dosing is as effective as standard dosing; there is a small risk of increased disease activity if intervals are extended too far.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, RELAPSING-REMITTING

Contacts and locations

Locations

Amsterdam UMC, location VU

Amsterdam, North Holland, 1081 HV, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.